Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TotalEnergies SE — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while TotalEnergies SE trades at $79.64 (market cap $173.13B). The key difference: TotalEnergies SE is far larger — about 4.3× Alnylam Pharmaceuticals, Inc.'s market cap, and TotalEnergies SE pays a 5.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TTE | |
|---|---|---|
Market Cap | $39.89B | $173.13B |
Sector | Health | Energy |
52-Week High | $491.22 | $93.60 |
52-Week Low | $278.09 | $57.39 |
Enterprise Value | $38.15B | $207.27B |
Dividend Yield | — | 5.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TTE trades at $78.5, up 0.35% today, with a neutral technical signal and mixed earnings history including a Q1 2026 beat. Valuation ratios appear attractive with a P/E of 11.65 and EV/EBITDA of 4.81. Recent news highlights strategic divestments and new LNG shipments, while cash flow trends show stabilization after recent declines.
Outlook is cautiously positive given strong analyst buy ratings (57.58%) and shareholder returns via dividends, but risks include revenue declines, geopolitical exposure, and regulatory pressures. The stock offers value characteristics with moderate growth prospects amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
